5243722026-01-012026-03-315243722026-03-315243722025-03-315243722025-04-012026-03-315243722026-01-012026-03-31in-capmkt:OtherExpenses1Member5243722025-04-012026-03-31in-capmkt:OtherExpenses1Member5243722026-03-31OtherNoncurrentFinancialAssetsDomain15243722026-03-31OtherNoncurrentFinancialAssetsDomain25243722026-03-31OtherNoncurrentAssetsDomain15243722026-03-31OtherCurrentFinancialAssetsDomain15243722026-03-31OtherCurrentAssetsDomain15243722026-03-31OtherNoncurrentFinancialLiabilitiesDomain15243722026-03-31OtherNoncurrentLiabilitiesDomain15243722026-03-31OtherCurrentFinancialLiabilitiesDomain15243722026-03-31OtherCurrentLiabilitiesDomain15243722026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15243722025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15243722026-01-012026-03-31RelatedPartyTransactionDomain15243722025-12-31RelatedPartyTransactionDomain15243722026-03-31RelatedPartyTransactionDomain15243722026-01-012026-03-31RelatedPartyTransactionDomain25243722025-12-31RelatedPartyTransactionDomain25243722026-03-31RelatedPartyTransactionDomain25243722026-01-012026-03-31RelatedPartyTransactionDomain35243722025-12-31RelatedPartyTransactionDomain35243722026-03-31RelatedPartyTransactionDomain35243722026-01-012026-03-31RelatedPartyTransactionDomain45243722025-12-31RelatedPartyTransactionDomain45243722026-03-31RelatedPartyTransactionDomain45243722026-01-012026-03-31RelatedPartyTransactionDomain55243722025-12-31RelatedPartyTransactionDomain55243722026-03-31RelatedPartyTransactionDomain55243722026-01-012026-03-31RelatedPartyTransactionDomain65243722025-12-31RelatedPartyTransactionDomain65243722026-03-31RelatedPartyTransactionDomain65243722026-01-012026-03-31RelatedPartyTransactionDomain75243722025-12-31RelatedPartyTransactionDomain75243722026-03-31RelatedPartyTransactionDomain75243722026-01-012026-03-31RelatedPartyTransactionDomain85243722025-12-31RelatedPartyTransactionDomain85243722026-03-31RelatedPartyTransactionDomain85243722026-01-012026-03-31RelatedPartyTransactionDomain95243722025-12-31RelatedPartyTransactionDomain95243722026-03-31RelatedPartyTransactionDomain95243722026-01-012026-03-31RelatedPartyTransactionDomain105243722025-12-31RelatedPartyTransactionDomain105243722026-03-31RelatedPartyTransactionDomain105243722026-01-012026-03-31RelatedPartyTransactionDomain115243722025-12-31RelatedPartyTransactionDomain115243722026-03-31RelatedPartyTransactionDomain115243722026-01-012026-03-31RelatedPartyTransactionDomain125243722025-12-31RelatedPartyTransactionDomain125243722026-03-31RelatedPartyTransactionDomain125243722026-01-012026-03-31RelatedPartyTransactionDomain135243722025-12-31RelatedPartyTransactionDomain135243722026-03-31RelatedPartyTransactionDomain135243722026-01-012026-03-31RelatedPartyTransactionDomain145243722025-12-31RelatedPartyTransactionDomain145243722026-03-31RelatedPartyTransactionDomain145243722026-01-012026-03-31RelatedPartyTransactionDomain155243722025-12-31RelatedPartyTransactionDomain155243722026-03-31RelatedPartyTransactionDomain155243722026-01-012026-03-31RelatedPartyTransactionDomain165243722025-12-31RelatedPartyTransactionDomain165243722026-03-31RelatedPartyTransactionDomain165243722026-01-012026-03-31RelatedPartyTransactionDomain175243722025-12-31RelatedPartyTransactionDomain175243722026-03-31RelatedPartyTransactionDomain175243722026-01-012026-03-31AuditorDomain15243722026-03-31Statement15243722026-01-012026-03-31Statement15243722026-03-31StatementDynamic1I1Statement15243722026-03-31StatementDynamic1I2Statement15243722026-03-31StatementDynamic1I3Statement15243722026-03-31StatementDynamic1I4Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares524372ORCHPHARMANOTLISTEDINE191A01027ORCHID PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-05-252026-05-19INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2026-05-2515:00:002026-05-2517:15:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-01-18www.orchidpharma.comtrue1falseNot Applicable as the Company has not defaulted on Loans and Debt Securities during the reporting period.2026-01-012026-03-31AuditedStandalone2376073000132963000250903600012094600004759000299349000195915000307700009149100037664700022083910003006450005392000306037000000030603700000003060370008820000314857000507191000106.036.03006.036.031. The above results for the quarter and year ended March 31 , 2026 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on May 25, 2026.The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results <BR> 2 The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. <BR> 3 a) The Government of India had consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes', which became effective from 21st November 2025. However, the new Rules are yet be notified even as on date. <BR> During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company recognised a provision of Rs. 711 .27 lakhs towards incremental estimated liabilities for past service cost relating to gratuity and leave, which was disclosed under "Exceptional items". <BR> Thereafter, based on subsequent FAQ's and clarifications issued by the Ministry of Labour, deliberations at various forums and detailed examination of various provisions of the above new Labour Codes, the Company, based on Actuarial Valuation, has determined that the incremental estimated liabilities as on March 31, 2026 on account of past service cost in relation to Gratuity and Leave liability amounted to only Rs.657.35 Lakhs. Hence the excess provision of Rs.53.92 Lakhs in December 2025 quarter has been reversed in the March 2026 quarter under "Exceptional items". The net impact of such re assessment has been appropriately accounted for in the statement of profit and loss. <BR> The Company continues to monitor the finalisation of Central 1 State Rules and further clarifications from the Government on other aspects of the Labour Codes and will account for any additional impact, if required, based on such developments. <BR> 4. 99,02,705 fully paid up Equity Shares of face value ~ 101- each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement (QIP) whereby proceeds of Rs.39180 Lakhs (Net of Share issue expenses) was raised. <BR> As on March 31 , 2026 the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : <BR> <BR> Statement of QIP Net Funds raised and utilisation <BR> Particulars Amount as stated in Total amount utilised Balance amount as on Remarks <BR> the Offer Document upto March 31, 2026 on March 31, 2026 kept <BR> Rs. In Lakhs Rs. In Lakhs in Fixed Deposits in lakhs <BR> <BR> 1)Investment in OBPL, subsidiary, <BR> for setting up Jammu <BR> Manufacturing Facility 13500 7302 6198 <BR> 2)Repayment/prepayment, in <BR> full or in part, of certain <BR> outstanding borrowings <BR> availed by the company 19546 19546 - <BR> 3)Funding capital expenditure <BR> requirements for setting up a <BR> new block at the API facility <BR> of the Company in Alathur, <BR> Tamil Nadu 36 36 - <BR> 4)General corporate purposes 6372 6372 0 # <BR> Total 39454 33256 6198 <BR> # As per QIP Offer Document the amount allocated for General Corporate Purpose (GCP) was Rs. 6098 Lakhs which was based on the propsoed net proceeds after issue expenses being Rs.39180 Lakhs. However, net proceeds transferred to Monitoring Agency Account was Rs. 39454 Lakhs as against the proposed Net Proceeds of Rs. 39180 Lakhs, therefore surplus Amount of Rs. 274 Lakhs has been included in GCP Balance as on March 31, 2026. The allocation among the objects has been revised vide Shareholder's Resolution dated September 20, 2025. <BR> <BR> 5. The operations of the Company falls under a single operating segment i.e., "Pharmaceuticals" in accordance with Ind AS 108 "Operating Segments" and hence no reporting as per Ind AS 108 is applicable. <BR> <BR> 6. The figures for the quarters ended 31st March, 2026 and 31st March, 2025 are the balancing figures between audited figures in respect of the full financial year and year to date figures up to the third quarter of the relevant financial years which were subjected to limited review. <BR> <BR> 7 The Company has submitted a petition with the Hon'ble National Company law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka laboratories Limited ("the Amalgamating Company") with the Company in compliance with Section 230-232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation letter from the BSE Limited and National Stock Exchange of India Limited ("stock exchanges") giving No objection to the said amalgamation. <BR> <BR> The requisite approvals of the concerned shareholders and creditors, as directed by the Hon'ble NCl T have been duly secured. Further, the Companies submitted the Joint Company Petition seeking approval on the Scheme of <BR> Amalgamation. During its hearing held on March 18, 2026, Hon'ble NClT reserved the matter for pronouncement of order, which is presently awaited. <BR> <BR> 8 The Company has successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH, Germany and Allecra Therapeutics SAS, France on October 29,2025 and August 01,2025 respectively. After the successful completion of above transactions, Orchid Pharma Limited now possesses 100% global ownership of Enmetazobactam (International Brand Name known as EXBLIFEP) (known as Orblicef in India), consolidating rights and control previously split across entities. This will mark the full repatriation of the first novel antibiotic molecule discovered in India, back to India. <BR> <BR> 9 The Company have acquired 100% Share Capital of Weilchensee 1272. V V GmbH, a Company incorporated under laws of Germany, now a Wholly owned subsidiary renamed as Orchid Pharma Europe GmbH w.e.f. July 30, <BR> 2025. <BR> <BR> 10 Figures of the previous period have been regroupted/reclassified Irestated wherever considered necessary2025-04-012026-03-31AuditedStandalone8113273000552419000866569200046233690001687200061851200088135100013235900035562400015197910008147878000517814000-657350004520790000000452079000000045207900089690004610480005071910001008.918.91008.918.91Other expenses376647000Other expenses151979100059168630009499770000059590007307980000073337400001824910000848510002643135000487117000407452000111413010002564114000026387110001239600064965400006310000330707100024936000463739000635986000000175011610005071910001319434800013701539000137015390001786198000000472480001833446000117040000211550001971641000958100043510000155223200015957420003854000160917700021748600013180001827981000379962200017501161000Right of use assets49289000Other financial assets35562000Other non current assets407452000Other financial assets6310000Other current assets463739000Lease Liabilities47248000Other Non Current liabilities21155000Lease Liabilities3854000Other current liabilities217486000132359000699601000-1409420000207190000713600000-12611200000035562400002561500011359000000-692320000-2388610000000-477722000-7243300007070640001159143000000-2725300001186396000000393740000000904840001657672000000000000000074247800000002608380000834465000-125373700000000000356198000416452000001871700000-78971000-1463120000-14631200015870800012396000Items that will not be recalssified to profit or loss88200008820000Items that will not be recalssified to profit or loss89690008969000000088200008969000Orchid Pharma Limited******Dhanuka Laboratories Limited******Holding CompanyPurchase of goods or services500000000Approved66404000054983000Orchid Pharma Limited******Dhanuka Laboratories Limited******Holding CompanyAny other transactionlease rents recived25000000Approved1475400005583000Orchid Pharma Limited******Dhanuka Laboratories Limited******Holding CompanySale of goods or services500000000Approved18698200011345000198328000Orchid Pharma Limited******DHANUKA AGRITECH LIMITED******Related Party under sec2(76)(1v)Any other transactionlease rents paid15000000Approved4278000057000Orchid Pharma Limited******DHANUKA AGRITECH LIMITED******Related Party under sec2(76)(1v)Any other transactionrental deposit paidApproval included with lease rents019100000Orchid Pharma Limited******ORBION PHARMACEUTICALS PRIVATE LIMITED******Associate CompanySale of goods or services50000000Approved156700000Orchid Pharma Limited******ORCHID BIO-PHARMA LIMITED******Wholly Owned Subsidiary companyLoan3500000000Approved40359100013130330001785881000Loan0.0012As per loan agreementUnsecuredFor investing in capital projectOrchid Pharma Limited******ORCHID BIO-PHARMA LIMITED******Wholly Owned Subsidiary companyInterest receivedAppoval included with loan given6925700000Orchid Pharma Limited******ORCHID BIO-PHARMA LIMITED******Wholly Owned Subsidiary companyAny other transactioncorporate gaurantee commission received60000000Approved33031000019551000Orchid Pharma Limited******OTSUKA CHEMICAL (INDIA) PVT LTD******Related Party under sec2(76)(1v)Purchase of goods or services4000000000Approved58510400098307000330211000Orchid Pharma Limited******Synmedic Laboratories******Related Party under sec2(76)(iii)Purchase of goods or services10000000Approved32400010001000Orchid Pharma Limited******Synmedic Laboratories******Related Party under sec2(76)(iii)Sale of goods or services50000000Approved30830007020001012000Orchid Pharma Limited******Synmedic Laboratories******Related Party under sec2(76)(iii)Any other transactionlease rents recived20000000Approved1004500003801000Orchid Pharma Limited******Orchid Pharma Europe GMBH******Wholly Owned Subsidiary companyAny other transactionShare capital investedN.A028950002895000Orchid Pharma Limited******Orchid Pharma Europe GMBH******Wholly owned Subsidiary companyLoanN.A38409000038409000Loan0.0006As per loan agreementUnsecuredFor meeting business requirementOrchid Pharma Limited******Orchid Pharma Europe GMBH******Wholly owned Subsidiary companyInterest receivedN.A6190000619000Orchid Pharma Limited******ORCHID BIO-PHARMA LIMITED******Wholly owned Subsidiary companyAny other transactionCorporate guarantee givenN.A258200000001675648000AuditedtrueSinghi & Cotrue2028-08-31QIP2023-06-2740000000002026-03-31trueCare Ratings Limitedtruetrue2025-09-20In view of changes in the business environment and to meet current strategic requirements, the Company has modified the allocation of the QIP Proceeds. The commencement of “new block at API Facility of the Company in Alathur” project has been postponed to a later stage. Therefore, QIP Proceeds allotted to API Facility in Alathur has been reallocated with the approval of shareholders at the AGM held on September 30, 2025, to mitigate such additional financial burden, improve profit and ensure the best possible utilization of the QIP proceeds in the overall interest of the Company and its shareholders.Remark 1: There is significant delay in the implementation of the manufacturing facility under Orchid Bio Pharma Limited in Jammu, however, extent of delay is not ascertainable. Comment: The Land acquisition task has been given to Land aggregator who is getting the land from various farmers. Getting the agreement signed from various farmers has taken time. Registration of the remaining land parcel is expect to be completed soon. Construction activity of Major Building is in advance stage. Installation of equipment's already started. Commercial operations are now expected to commence by February 2027. Remark 2: Entire amount allotted has been utilized as of Jun-25. Comment: Entire amount allotted as per the revised object schedule (Rs. 36 Lakhs) was utilised as of June 2025. Hence no amount remain unutilised. NILKapil DayyaCompany Secretary and Compliance OfficerGurugram2026-05-25Investment in Orchid Bio Pharma Limited for setting up Manufacturing Facility in JammuNot Applicable90000000013500000007302000000The company has transferred Rs. 8.41 crores from MA account to CC account as reimbursement of investment already made in OBPL from its own sources. <br></br> <br></br> Further, the Allocation of Rs.45 Crores from Fund raised for API Facility at Alathur.Repayment or prepayment, in full or in part, of certain outstanding borrowings availed by our CompanyNot Applicable1410000000195460000019546000000Allocation of Rs.54.46 Crores from Fund raised for API Facility at Alathur.Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil NaduNot Applicable998200000360000036000000Allocated the Funds to other objects of the QIP with the approval of shareholders.General corporate purposesNot Applicable6098000006372000006372000000As per the QIP offer document the amount allocated for GCP was Rs.6098 Lakhs which was on the basis of proposed net proceeds after issue expenses, being Rs.39180 Lakhs. However, net Proceeds transferred to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39180 Lakhs, therefore the GCP was revised to Rs.274 lakhs has been included in the GCP and therefore the GCP balance was revised to Rs.6372 Lakhs.